接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗前后，成年囊性纤维化相关糖尿病患者的连续血糖监测模式
CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy.
作者信息
Crow Hanna, Bengtson Charles, Shi Xiaosong, Graves Leland, Anabtawi Abeer
机构信息
University of Kansas Medical Center, Department of Internal Medicine, Division of Endocrinology, Metabolism & Clinical Pharmacology, 4000 Cambridge Blvd, Kansas City, KS 66160, USA.
University of Kansas Medical Center, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, 4000 Cambridge Blvd, Kansas City, KS 66160, USA.
出版信息
J Clin Transl Endocrinol. 2022 Oct 1;30:100307. doi: 10.1016/j.jcte.2022.100307. eCollection 2022 Dec.
Abstract
Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition status. However, data regarding effects of CFTR modulators on glycemic control among those with CFRD is lacking. In this retrospective study, CGM data was analyzed to determine effect of elexacaftortezacaftor- ivacaftor therapy (ETI), a CFTR modulator, on glucose control among patients with CFRD. No difference was seen in glucose patterns after 3- and 6- months of starting ETI.
摘要
囊性纤维化相关糖尿病（CFRD）是囊性纤维化的一种常见并发症，与更差的预后和更高的死亡率相关。囊性纤维化跨膜传导调节因子基因（CFTR）调节剂已显示出对肺功能、肺部急性加重和营养状况有良好影响。然而，关于CFTR调节剂对CFRD患者血糖控制影响的数据尚缺。在这项回顾性研究中，分析了连续血糖监测（CGM）数据，以确定CFTR调节剂依列卡福-替扎卡福-依伐卡托疗法（ETI）对CFRD患者血糖控制的影响。开始ETI治疗3个月和6个月后，血糖模式未见差异。
相似文献
1
CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy.
J Clin Transl Endocrinol. 2022 Oct 1;30:100307. doi: 10.1016/j.jcte.2022.100307. eCollection 2022 Dec.
2
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
J Cyst Fibros. 2022 Mar;21(2):258-263. doi: 10.1016/j.jcf.2021.09.001. Epub 2021 Sep 14.
3
The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
Cureus. 2023 Jul 11;15(7):e41697. doi: 10.7759/cureus.41697. eCollection 2023 Jul.
4
Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis.
Clin Nutr ESPEN. 2023 Dec;58:73-78. doi: 10.1016/j.clnesp.2023.08.028. Epub 2023 Aug 25.
5
Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Front Endocrinol (Lausanne). 2024 Feb 6;15:1293709. doi: 10.3389/fendo.2024.1293709. eCollection 2024.
6
Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Respir Med Case Rep. 2022 Nov 7;40:101775. doi: 10.1016/j.rmcr.2022.101775. eCollection 2022.
7
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.
J Clin Transl Endocrinol. 2023 Jun 24;33:100320. doi: 10.1016/j.jcte.2023.100320. eCollection 2023 Sep.
8
Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis.
Int Forum Allergy Rhinol. 2024 Nov;14(11):1692-1699. doi: 10.1002/alr.23400. Epub 2024 Jul 3.
9
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
Children (Basel). 2023 Mar 15;10(3):554. doi: 10.3390/children10030554.
10
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
引用本文的文献
1
Utility of Continuous Glucose Monitors for Improved Detection of Cystic Fibrosis-Related Diabetes.
Pediatr Pulmonol. 2025 Aug;60(8):e71267. doi: 10.1002/ppul.71267.
2
Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor.
J Clin Transl Endocrinol. 2025 Jul 2;41:100407. doi: 10.1016/j.jcte.2025.100407. eCollection 2025 Sep.
3
Sex disparities in cystic fibrosis in the era of highly effective modulator treatment.
BMC Pulm Med. 2025 May 2;25(1):212. doi: 10.1186/s12890-025-03621-0.
4
One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study.
Life (Basel). 2024 Oct 16;14(10):1309. doi: 10.3390/life14101309.
5
Development of a programmable automated cell culture system to study the lung pathophysiology of Cystic Fibrosis-related diabetes.
Heliyon. 2024 Sep 19;10(18):e37977. doi: 10.1016/j.heliyon.2024.e37977. eCollection 2024 Sep 30.
6
The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes.
J Clin Transl Endocrinol. 2024 Feb 28;35:100332. doi: 10.1016/j.jcte.2024.100332. eCollection 2024 Mar.
7
Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.
Front Pharmacol. 2023 Dec 14;14:1275470. doi: 10.3389/fphar.2023.1275470. eCollection 2023.
8
The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
Cureus. 2023 Jul 11;15(7):e41697. doi: 10.7759/cureus.41697. eCollection 2023 Jul.
9
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.
J Clin Transl Endocrinol. 2023 Jun 24;33:100320. doi: 10.1016/j.jcte.2023.100320. eCollection 2023 Sep.
10
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
Front Pharmacol. 2023 Mar 21;14:1158207. doi: 10.3389/fphar.2023.1158207. eCollection 2023.
本文引用的文献
1
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
J Cyst Fibros. 2022 Mar;21(2):258-263. doi: 10.1016/j.jcf.2021.09.001. Epub 2021 Sep 14.
2
Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
J Diabetes Complications. 2021 Jun;35(6):107845. doi: 10.1016/j.jdiacomp.2020.107845. Epub 2021 Jan 5.
3
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
J Cyst Fibros. 2021 Mar;20(2):333-338. doi: 10.1016/j.jcf.2020.09.001. Epub 2020 Sep 8.
4
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
Ann Am Thorac Soc. 2021 Jan;18(1):75-83. doi: 10.1513/AnnalsATS.202002-144OC.
5
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
J Cyst Fibros. 2020 Sep;19(5):712-716. doi: 10.1016/j.jcf.2020.03.002. Epub 2020 Mar 19.
6
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
7
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
8
cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data.
PLoS One. 2019 Oct 11;14(10):e0216851. doi: 10.1371/journal.pone.0216851. eCollection 2019.
9
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10.
10
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.
Sci Rep. 2019 May 10;9(1):7234. doi: 10.1038/s41598-019-43652-2.
Zotero 插件